Physician profile
Eileen Schwartz
NPI 1043308299
$9,996.79
in general payments reported to CMS, 2019-2025
16 companies · $2,389 in 2025
The $2,389 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $246 · 2021: $1,387 · 2022: $1,432 · 2023: $2,154 · 2024: $1,944 · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,475 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,474.52 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,600.19 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Alkermes, INC. | $1,490.92 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,223.48 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $1,111.71 | 2019-2025 | Abilify Maintena, Rexulti |
| Abbvie INC. | $1,106.37 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $947.64 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $844.04 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $669.32 | 2021-2025 | Ingrezza |
| Indivior INC. | $361.33 | 2019-2025 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $250.45 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $167.13 | 2024-2025 | Fanapt |
| Allergan, INC. | $63.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $59.03 | 2021 | |
| Braeburn INC. | $55.51 | 2024-2025 | Brixadi |
| Axsome Therapeutics, INC. | $34.67 | 2023-2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.